-+ 0.00%
-+ 0.00%
-+ 0.00%

TenNor Therapeutics Enrolls First Patient in Phase IIb Rifaquizinone Trial for Prosthetic Joint Infection

PUBT·10/23/2026 00:03:07
Listen to the news
TenNor Therapeutics Enrolls First Patient in Phase IIb Rifaquizinone Trial for Prosthetic Joint Infection
  • TenNor Therapeutics on Oct. 23, 2026, announced first-patient enrollment in a Phase IIb trial of rifaquizinone for prosthetic joint infection.
  • The randomized, controlled study plans to enroll 40 adults to evaluate intra-articular injections alongside systemic antimicrobial therapy without debridement or replacement surgery.
  • Researchers will evaluate efficacy, safety and drug exposure, with the primary efficacy assessment six months after treatment begins.
  • The enrollment milestone advances clinical development but does not establish the treatment’s effectiveness.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tennor Therapeutics (Suzhou) Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261023-12380630), on October 23, 2026, and is solely responsible for the information contained therein.